

Showcasing research from Professor José M. Vila and Alexandra Fernandes' laboratories, Universidad de Santiago de Compostela, Santiago de Compostela, 15782 Spain and NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal.

Effect of mono- and dinuclear thiosemicarbazone platinumacycles in the proliferation of a colorectal carcinoma cell line

Herein are described the synthesis and characterization of a series of thiosemicarbazone platinumacycles. Their activity towards HCT116 and A2780 cancer cell lines, as well as normal fibroblasts, was explored and conclusions about the influence of their structures were drawn based on the results, putting forward their high selectivity and low  $IC_{50}$  values.

As featured in:



See José M. Vila, Alexandra Fernandes *et al.*, *Dalton Trans.*, 2024, 53, 17803.

Cite this: *Dalton Trans.*, 2024, **53**, 17803

## Effect of mono- and dinuclear thiosemicarbazone platinacycles in the proliferation of a colorectal carcinoma cell line†

Francisco Reigosa-Chamorro,<sup>‡a</sup> Sandra Cordeiro,<sup>‡b,c</sup> M. Teresa Pereira,<sup>a</sup> Beatriz Filipe,<sup>ID b,c</sup> Pedro V. Baptista,<sup>ID b,c</sup> Alexandra R. Fernandes<sup>ID \*b,c</sup> and José M. Vila<sup>ID \*a</sup>

Herein, we describe the synthesis and characterization of a series of thiosemicarbazone platinacycles. Their activity towards HCT116 and A2780 cancer cell lines as well as normal fibroblasts was explored and conclusions about the influence of their structures were drawn based on the results. Ligands **L1–3**, tetra-nuclear compounds **[Pt(L1–3)]<sub>4</sub>**, **[Pt(L1–3)(PPh<sub>3</sub>)]**, and **[Pt(L1–L3)<sub>2</sub>(Ph<sub>2</sub>P(CH<sub>2</sub>)<sub>4</sub>PPh<sub>2</sub>)]**, and phosphine derivatives, were deemed unpromising owing to their lack of activity. However, mono-coordinated diphosphine complexes **[Pt(L1–L3)(Ph<sub>2</sub>PCH<sub>2</sub>PPh<sub>2</sub>-P)]** showed high selectivity and low IC<sub>50</sub> values, and their antiproliferative activity was further studied. The three studied derivatives **3a**, **3b** and **3c** showed a fast internalization of HCT116 colorectal cancer cells with similar IC<sub>50</sub> values, which induced a depolarization of mitochondrial membrane potential, with the subsequent triggering of apoptosis and autophagy in the case of **3c**. In the case of compounds **3a** and **3b**, cell death mechanisms (extrinsic and intrinsic apoptosis, respectively) were triggered *via* the induction of reactive oxygen species (ROS). The three compounds were not toxic to a chicken embryo *in vivo* (after 48 h), and, importantly, showed an anti-angiogenic potential after exposure to the IC<sub>50</sub> of compounds **3a**, **3b** and **3c**.

Received 21st May 2024,  
Accepted 20th August 2024

DOI: 10.1039/d4dt01490a

rsc.li/dalton

## Introduction

Since the seminal paper by Cope and Siekman<sup>1</sup> describing cyclometallated compounds, *i.e.*, metallacycles, achieving the activation of aromatic C–H bonds using transition metals was published, the chemistry of such species has attracted much attention. Although many transition metals can potentially be applied to achieve corresponding metallacycles, the primary ones include palladium and platinum. This is a result of the numerous applications of these two transition metals in reactivity,<sup>2–4</sup> metallomesogens,<sup>5,6</sup> and synthetic chemistry,<sup>7,8</sup> where they are used in the functionalization of aromatic

carbons through insertion reactions.<sup>9,10</sup> Palladium and platinum have also found application in catalysis after the discovery of phosphine palladacycles by Herrmann *et al.*<sup>11–13</sup> Furthermore, being of particular note are the Suzuki<sup>14–19</sup> and Mizoroki–Heck cross-coupling reactions.<sup>19,20</sup> One application that has expanded the most for obvious reasons is their usage as antineoplastic substances, where the functionality of metallacycles is mainly marked by palladium or platinum.<sup>21–26</sup> The choice of the ligand in the synthesis of new compounds is of great importance, especially when bioactive applications are to be considered, since their properties will depend on the final structure of the compound. Thiosemicarbazone ligands are typical ligands in cyclometallation chemistry owing to the ease of their preparation *via* a simple condensation reaction, which is also compatible with a number of functional groups. Their selection is enhanced because they are bioactive on their own<sup>27</sup> as well as when they are combined with the metals of coordination compounds and cyclometallated species.<sup>28</sup> Their effects as antiplasmodic agents were studied for years, but research interests and new findings have shifted their application to other diseases such as cancer.<sup>29</sup> We have reported that in thiosemicarbazone metallacycles, the organic ligand is able to bind to a metal centre as tridentate [C,N,S] in a tetra-nuclear<sup>30</sup> structure through M–S<sub>chelating</sub> and M–S<sub>bridging</sub> bonds.

<sup>a</sup>Departamento de Química Inorgánica, Universidade de Santiago de Compostela, Avenida das Ciencias s/n, 15782 Santiago de Compostela, Spain.

E-mail: josemanuel.vila@usc.es

<sup>b</sup>Associate Laboratory i4HB – Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal.

E-mail: ma.fernandes@fct.unl.pt

<sup>c</sup>UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal

† Electronic supplementary information (ESI) available. CCDC 2309646 (**1b**) and 2309120 (**2c**). For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4dt01490a>

‡ Both authors contributed equally.



This favours the addition of an appropriate leaving group on the metal in the resulting mononuclear compound, holding fast the thiosemicarbazone/metal moiety. This safeguards metallacycle structural integrity during the transport in biological fluids until it reaches cancer cells, securing its biological/drug activity. This also allows to modify the characteristics of the compounds with diverse ancillary ligands, which has proved to be vital in the proficiency of the parent compound in catalytic reactions, spectroscopic and emissive chemiluminescence and antiproliferative effect. In this sense, phosphine ligands can be a great way to add variability to the resulting structures by using different ligands and changing the reaction conditions. Our previous experience with cyclometallated compounds tested the potential of mononuclear and dinuclear species as anticancer agents. The results allowed us to conclude that the inclusion of a second metal *via* palladacycle metallo-ligands bearing a monocoordinated diphosphine did not produce a noticeable improvement, and that the combination of the boronic acid function and dppm showed great potential. Nevertheless, the enhanced effect could not be attributed to one factor alone. Furthermore, it was unclear if all types of boronic acid derivatives, regardless of the ancillary ligands, could be as effective.<sup>26</sup> The results presented here confirm the effectiveness of the platinum analogues, and point to the dppm ligand as a key structural moiety in the biological effect of these species. In the present work, we aimed to expand on the knowledge of the family of thiosemicarbazone platinacycles by adjustment of the imine groups and the ancillary ligands in a series of compounds derived from acetylphenylboronic acid to determine the effect of this tuning in their bioactivity as anticancer drugs.

## Experimental section

### General procedures

All solvents were used without any previous purification. All chemicals were of reagent grade. The phosphines PPh<sub>3</sub> (triphenylphosphine), PPh<sub>2</sub>(CH<sub>2</sub>)PPh<sub>2</sub> [bis(diphenylphosphino) methane, dppm] and PPh<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>PPh<sub>2</sub> [bis(diphenylphosphino)-butane, dppb] were purchased from Sigma-Aldrich. Elemental analyses were performed in a THERMO FINNIGAN, model FLASH 1112. IR spectra were acquired with a JASCO FT/IR-4600 spectrometer equipped with an ATR, model ATR-PRO ONE. The NMR spectra were acquired on Varian INOVA 400 or Bruker DPX-250 spectrometers, using the solvent signal (CDCl<sub>3</sub>,  $\delta$  <sup>1</sup>H = 7.26, DMSO-d<sub>6</sub>,  $\delta$  <sup>1</sup>H = 2.50; acetone-d<sub>6</sub>,  $\delta$  <sup>1</sup>H = 2.05), or external H<sub>3</sub>PO<sub>4</sub> (85%), as appropriate. Coupling constants are reported in Hz.

### Synthesis of the ligands

**L1 (a)** 4-Acetylphenylboronic acid (500 mg, 3.05 mmol) was added to 3-thiosemicarbazide (277.92 mg, 3.05 mmol), hydrochloric acid (35%, 0.65 cm<sup>3</sup>) and water (40 cm<sup>3</sup>), resulting in a clear solution that was stirred at room temperature (RT) for 3 h. The formed white solid powder was filtered off, washed

with cold water, and dried *in vacuo*. White solid. Yield: 650.7 mg, 90%. Anal. Found: 45.8; H, 5.2; N, 17.7; S, 13.5%; C<sub>9</sub>H<sub>12</sub>BN<sub>3</sub>O<sub>2</sub>S (237.08 g mol<sup>-1</sup>) requires C, 45.6; H, 5.1; N, 17.7; S, 13.5%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3458;  $\nu$ (N-H) 3272, 3330;  $\nu$ (C=N) 1596;  $\nu$ (B-O) 1352;  $\nu$ (C=S) 813. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>,  $\delta$ ): 10.24 (s, 1H, NNH), 8.31 (s, 1H, NH<sub>2</sub>), 8.14 (s, 2H, B(OH)<sub>2</sub>), 7.96 (s, 1H, NH<sub>2</sub>), 7.89 (vd, *N* = 7.8 Hz, 2H, H<sub>2</sub>/H<sub>6</sub>), 7.78 (v, *N* = 7.8 Hz, 2H, H<sub>3</sub>/H<sub>5</sub>), 2.29 (s, 3H, MeC=N).

**L2 (b)** was prepared similarly from 3.05 mmol of acetylphenylboronic acid and methylthiosemicarbazone. White solid. Yield: 719.8 mg, 94%. Anal. Found: C, 47.6; H, 5.5; N, 16.8; S, 12.8%; C<sub>10</sub>H<sub>14</sub>BN<sub>3</sub>O<sub>2</sub>S (251.11 g mol<sup>-1</sup>) requires C, 47.8; H, 5.6; N, 16.7; S, 12.8%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3500;  $\nu$ (N-H) 3314, 3341;  $\nu$ (C=N) 1595;  $\nu$ (B-O) 1363;  $\nu$ (C=S) 831. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>,  $\delta$ ): 10.26 (s, 1H, NNH), 8.49 (br, 1H, NHMe), 8.17 (s, 2H, B(OH)<sub>2</sub>), 7.90 (d, *N* = 7.6 Hz, 2H, H<sub>2</sub>/H<sub>6</sub>), 7.80 (vd, *N* = 7.8 Hz, 2H, H<sub>3</sub>/H<sub>5</sub>), 3.03 (d, <sup>3</sup>*J* = 4.0 Hz, 3H, NHMe), 2.29 (s, 3H, MeC=N).

**L3 (c)** was made from 3.05 mmol of acetylphenylboronic acid and methylthiosemicarbazone following the same procedure. White solid. Yield: 768.1 mg, 95%. Anal. Found: C, 50.0; H, 6.1; N, 16.0; S, 12.0%; C<sub>11</sub>H<sub>16</sub>BN<sub>3</sub>O<sub>2</sub>S (265.14 g mol<sup>-1</sup>) requires C, 49.8; H, 6.1; N, 15.9; S, 12.1%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3450;  $\nu$ (N-H) 3317, 3321;  $\nu$ (C=N) 1592;  $\nu$ (B-O) 1357;  $\nu$ (C=S) 819. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>,  $\delta$ ): 10.16 (s, 1H, NNH), 8.55 (br, 1H, NHMe), 8.13 (s, 2H, B(OH)<sub>2</sub>), 7.88 (vd, *N* = 7.8 Hz, 2H, H<sub>2</sub>/H<sub>6</sub>), 7.80 (vd, *N* = 7.8 Hz, 2H, H<sub>3</sub>/H<sub>5</sub>), 3.62 (dq, <sup>3</sup>*J* = 7.0 Hz, 2H, CH<sub>2</sub>), 2.28 (s, 3H, MeC=N), 1.14 (t, <sup>3</sup>*J* = 7.0 Hz, 3H, Me).

**[PtL1]<sub>4</sub> (1a)**. **L1** (50 mg, 0.21 mmol) was added to a suspension of potassium tetrachloroplatinate (0.18 mmol, 1 eq.) in a mixture of ethanol (20 mL) and water (0.5 mL). The mixture was stirred at 55 °C for 48 h. Ethanol was removed under reduced pressure and the resulting orange solid was washed with water, centrifuged, and dried *in vacuo*. Yield: 84.9 mg, 92%. Anal. Found: C, 24.8; H, 2.2; N, 9.6; S, 7.6%; (C<sub>9</sub>H<sub>10</sub>BN<sub>3</sub>O<sub>2</sub>PtS)<sub>4</sub> (1720.6 g mol<sup>-1</sup>) requires C, 25.1; H, 2.3; N, 9.8; S, 7.5%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3448;  $\nu$ (N-H) 3289, 3162;  $\nu$ (C=N) 1577;  $\nu$ (B-O) 1317. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>,  $\delta$ ): 7.83 (s, 1H, H<sub>5</sub>), 7.16 (d, <sup>3</sup>*J* = 7.6 Hz, 1H, H<sub>3</sub>), 6.60 (s, 2H, NH<sub>2</sub>), 6.41 (d, <sup>3</sup>*J* = 7.6 Hz, 1H, H<sub>2</sub>), 1.88 (s, 3H, MeC=N).

**[PtL2]<sub>4</sub> (1b)** was prepared from **L2** (50 mg, 0.20 mmol) and potassium tetrachloroplatinate (75 mg, 0.18 mmol) following the same procedure. Yield: 72.5 mg, 82%. Anal. Found: C, 27.0; H, 2.5; N, 9.3; S, 7.5%; (C<sub>10</sub>H<sub>12</sub>BN<sub>3</sub>O<sub>2</sub>PtS)<sub>4</sub> (1776.72 g mol<sup>-1</sup>) requires C, 27.1; H, 2.7; N, 9.5; S, 7.2%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3472;  $\nu$ (N-H) 3305, 3210;  $\nu$ (C=N) 1582;  $\nu$ (B-O) 1351. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>,  $\delta$ ): 7.93 (s, 1H, H<sub>5</sub>), 7.58 (s, 2H, B(OH)<sub>2</sub>), 7.36 (d, <sup>3</sup>*J* = 7.6 Hz, 1H, H<sub>3</sub>), 6.70 (d, <sup>3</sup>*J* = 7.6 Hz, 1H, H<sub>2</sub>), 6.49 (s, 1H, NHMe), 2.93 (d, <sup>3</sup>*J* = 4.7 Hz, 3H, NHMe), 1.51 (s, 3H, MeC=N).

**[PtL3]<sub>4</sub> (1c)** was prepared employing **L3** (53 mg, 0.20 mmol) and potassium tetrachloroplatinate (75 mg, 0.18 mmol) as starting materials. Yield: 69.1 mg, 80%. Anal. Found: C, 28.9; H, 3.1; N, 9.4; S, 7.2%; (C<sub>11</sub>H<sub>14</sub>BN<sub>3</sub>O<sub>2</sub>PtS)<sub>4</sub> (1832.84 g mol<sup>-1</sup>) requires C, 28.8; H, 3.1; N, 9.2; S, 7.0%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3419;  $\nu$ (N-H) 3244, 2972;  $\nu$ (C=N) 1575;  $\nu$ (B-O) 1320. <sup>1</sup>H NMR



(400 MHz, DMSO- $d_6$ ,  $\delta$ ): 7.92 (s, 1H, H5), 7.35 (d,  $^3J = 7.6$  Hz, 1H, H3), 6.68 (d,  $^3J = 7.6$  Hz, 1H, H2), 6.29 (s, 1H, NH<sub>Et</sub>), 1.54 (s, 3H, MeC=N), 1.11 (t,  $^3J = 7.2$  Hz, 3H, Me).

**[PtL1(PPh<sub>3</sub>)] (2a).** Compound **1a** (50 mg, 0.029 mmol) and triphenylphosphine (30.5 mg, 0.11 mmol, 1 : 4) were added in a carousel reaction flask fitted with a stirring rod, and vacuum/argon cycles were performed; then, deoxygenated acetone was added through a syringe. This mixture was stirred for 6 h to yield a clear solution. After solvent removal, the resulting solid was triturated with dichloromethane/*n*-hexane and centrifuged. The coral solid was then dried under vacuum. Yield: 63.6 mg, 79%. Anal. Found: C, 46.6; H, 3.6; N, 6.2; S, 4.8%; C<sub>27</sub>H<sub>25</sub>BN<sub>3</sub>O<sub>2</sub>PPTs (692.44 g mol<sup>-1</sup>) requires C, 46.8; H, 3.7; N, 6.1; S, 4.6%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3452;  $\nu$ (N-H) 3049;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1328. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ):  $\delta$  7.71–7.64 (m, 6H, *o*-PPh<sub>3</sub>), 7.49–7.39 (m, 11H, PPh<sub>3</sub>), 7.31 (dd,  $J = 7.5, 1.2$  Hz, 1H, H3), 6.98 (d,  $J = 7.6$  Hz, 1H, H2), 6.96 (q,  $J = 1.8$  Hz, 1H, H5), 6.05 (s, 2H, NH<sub>2</sub>), 2.43 (s, 3H, MeC=N). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  23.91, <sup>1</sup>J(PtP) = 3892.86 Hz.

The remaining phosphine and/or diphosphine derivatives were prepared similarly.

**[PtL2(PPh<sub>3</sub>)] (2b)** was prepared from 0.1 mmol of triphenylphosphine and 0.025 mmol of **1b**. Yield: 56.5 mg, 71%. Anal. Found: C, 47.4; H, 3.8; N, 6.0; S, 4.4%; C<sub>28</sub>H<sub>27</sub>BN<sub>3</sub>O<sub>2</sub>PPTs (706.47 g mol<sup>-1</sup>) requires C, 47.6; H, 3.8; N, 5.9; S, 4.5%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3412;  $\nu$ (N-H) 3324;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1335. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ): 7.75–7.63 (m, 6H, PPh<sub>3</sub>), 7.47–7.35 (m, 9H, PPh<sub>3</sub>), 7.30 (d,  $^3J = 7.5$  Hz, 1H, H3), 6.98 (d,  $^3J = 8.0$  Hz, 1H, H2), 6.94 (d,  $^4J = 1.6$  Hz, 1H, H5), 6.04 (s, 1H, NHMe), 2.96 (d,  $^3J = 4.5$  Hz, 3H, NHMe), 2.42 (s, 3H, Me). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  23.91 <sup>1</sup>J(PtP) = 3888 Hz.

**[PtL3(PPh<sub>3</sub>)] (2c)** was prepared from 0.1 mmol of triphenylphosphine and 0.025 mmol of **1c**. Yield: 62.9 mg, 80%. Anal. Found: C, 48.1; H, 4.0; N, 5.9; S, 4.6%; C<sub>29</sub>H<sub>29</sub>BN<sub>3</sub>O<sub>2</sub>PPTs (720.50 g mol<sup>-1</sup>) requires C, 48.3; H, 4.1; N, 5.8; S, 4.5%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3434;  $\nu$ (N-H) 3052;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1330. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ): 7.67 (dd,  $^3J$ (PH) = 11.3 Hz,  $^3J = 7.7$  Hz, 6H, *o*-PPh<sub>3</sub>), 7.45 (dd,  $J = 8.2, 5.2$  Hz, 9H), 7.31 (d,  $^3J = 7.6$  Hz, 1H, H3), 6.99 (d,  $^3J = 8.3$  Hz, 1H, H2), 6.96 (s, 1H, H5), 6.11 (s, 1H, NH<sub>Et</sub>), 3.40 (p,  $^3J = 6.9$  Hz, 2H, CH<sub>2</sub>), 2.44 (s, 3H, Me), 1.17 (td,  $^3J = 7.1, 2.3$  Hz, 3H, Me). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  23.83 <sup>1</sup>J(PtP) = 3912.3 Hz.

**[PtL1(dppm-P)] (3a)** was prepared from 0.2 mmol of dppm and 0.05 mmol of **1a**. Yield: 101.3 mg, 57%. Anal. Found: C, 49.8; H, 3.7; N, 5.1; S, 3.8%; C<sub>34</sub>H<sub>32</sub>BN<sub>3</sub>O<sub>2</sub>P<sub>2</sub>Ts (814.55 g mol<sup>-1</sup>) requires C, 50.1; H, 3.9; N, 5.2; S, 3.9%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3444;  $\nu$ (N-H) 3051;  $\nu$ (N-H) 1575;  $\nu$ (B-O) 1330. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ): 7.90–7.82 (m, 4H, PPh<sub>2</sub>), 7.42–7.33 (m, 6H, PPh<sub>2</sub>), 7.33–7.27 (m, 4H, PPh<sub>2</sub>), 7.21–7.13 (m, 5H, PPh<sub>2</sub>), 7.03 (d,  $J = 1.6$  Hz, 1H, H5), 6.89 (d,  $^3J = 7.6$  Hz, 1H, H2), 6.28 (s, 2H, B(OH)<sub>2</sub>), 6.08 (s, 2H, NH<sub>2</sub>), 3.72–3.51 (m, 2H, PCH<sub>2</sub>P), 2.37 (s, 3H, MeC=N). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  12.54 (d, <sup>2</sup>J(P-P) = 78.9 Hz, <sup>3</sup>J(PtP) = 3863.70 Hz), -23.51 (d, <sup>2</sup>J(P-P) = 79.0 Hz, <sup>3</sup>J(PtP) = 77.76 Hz).

**[PtL2(dppm-P)] (3b)** was prepared from 0.2 mmol of dppm and 0.05 mmol of **1b**. Yield: 88.8 mg, 62%. Anal. Found: C,

50.6; H, 4.1; N, 5.0; S, 3.8%; C<sub>35</sub>H<sub>34</sub>BN<sub>3</sub>O<sub>2</sub>P<sub>2</sub>Ts (828.58 g mol<sup>-1</sup>) requires C, 50.7; H, 4.1; N, 5.1; S, 3.9%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3391;  $\nu$ (N-H) 3051;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1331. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ): 7.86 (t,  $J = 9.7$  Hz, 4H, PPh<sub>2</sub>), 7.33 (q,  $J = 7.3$  Hz, 10H, PPh<sub>2</sub>), 7.18 (p,  $J = 7.7$  Hz, 6H, PPh<sub>2</sub>), 7.03 (s, 1H, H5), 6.90 (d,  $^3J = 7.6$  Hz, 1H, H2), 6.32 (s, 2H, B(OH)<sub>2</sub>), 6.12 (s, 1H, NHMe), 3.72–3.55 (m, 2H, PCH<sub>2</sub>P), 2.99 (t,  $^3J = 3.5$  Hz, 3H, NHMe), 2.37 (s, 3H, MeC=N). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  12.55 (d, <sup>2</sup>J(P-P) = 79.5 Hz, <sup>1</sup>J(Pt-P) = 3860.46 Hz), -23.59 (d, <sup>2</sup>J(P-P) = 79.0 Hz, <sup>3</sup>J(PtP) = 38.6 Hz).

**[PtL3(dppm-P)] (3c)** was prepared from 0.2 mmol of dppm and 0.05 mmol of **1c**. Yield: 89.4 mg, 63%. Anal. Found: C, 51.1; H, 4.2; N, 5.1; S, 3.9%; C<sub>36</sub>H<sub>36</sub>BN<sub>3</sub>O<sub>2</sub>P<sub>2</sub>Ts (842.60 g mol<sup>-1</sup>) requires C, 51.3; H, 4.3; N, 5.0; S, 3.8%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3391;  $\nu$ (N-H) 3054;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1334. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ ,  $\delta$ ): 7.86 (t,  $J = 9.8$  Hz, 4H), 7.49 (s, 1H), 7.33 (q,  $J = 7.5$  Hz, 10H), 7.18 (t,  $J = 8.4$  Hz, 6H), 7.03 (s, 1H, H5), 6.89 (dd,  $^3J = 7.6, 2.5$  Hz, 1H, H<sub>2</sub>), 6.31 (d,  $J = 2.5$  Hz, 2H, B(OH)<sub>2</sub>), 6.12 (s, 1H, NH<sub>Et</sub>), 3.62 (dd,  $J = 17.9, 9.8$  Hz, 2H, PCH<sub>2</sub>P), 3.43 (p,  $^3J = 7.2$  Hz, 2H, PCH<sub>2</sub>P), 2.36 (d,  $J = 2.5$  Hz, 3H, MeC=N), 1.20 (td,  $^3J = 7.2, 2.3$  Hz, 3H, Me). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  12.55 (d, <sup>2</sup>J(P-P) = 78.9 Hz, <sup>1</sup>J(Pt-P) = 3859.6 Hz), -23.53 (d, <sup>2</sup>J(P-P) = 78.4 Hz, <sup>3</sup>J(Pt-P) = 38.7 Hz).

**[(PtL1)<sub>2</sub>( $\mu$ -dppb)] (4a)** was prepared from 0.05 mmol of dppb and 0.025 mmol of **1a**. Yield: 53.8 mg, 72%. Anal. Found: C, 42.6; H, 3.7; N, 6.7; S, 4.7%; C<sub>46</sub>H<sub>48</sub>B<sub>2</sub>N<sub>6</sub>O<sub>4</sub>P<sub>2</sub>Ts<sub>2</sub> (1286.78 g mol<sup>-1</sup>) requires C, 43.0; H, 3.8; N, 6.5; S, 5.0%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3389;  $\nu$ (N-H) 3050;  $\nu$ (C=N) 1574;  $\nu$ (B-O) 1331. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ )  $\delta$  7.84–7.71 (m, 8H, PPh<sub>2</sub>), 7.50 (q,  $J = 9.4, 8.1$  Hz, 6H, PPh<sub>2</sub>), 7.40 (td,  $J = 5.2, 2.7$  Hz, 6H, PPh<sub>2</sub>), 7.37–7.30 (m, 3H, PPh<sub>2</sub>), 7.05 (d,  $^3J = 7.5$  Hz, 2H, H<sub>2</sub>), 6.94 (t,  $J = 6.6$  Hz, 2H, H<sub>5</sub>), 6.43 (s, 4H, B(OH)<sub>2</sub>), 6.17 (s, 4H, NH<sub>2</sub>), 2.35 (d,  $J = 5.9$  Hz, 6H, MeC=N), 2.30–2.16 (m, 4H, PCH<sub>2</sub>), 1.92–1.85 (m, 4H, CH<sub>2</sub>). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  16.04, 15.06, <sup>1</sup>J(PtP) = 3818.23 Hz.

**[(PtL2)<sub>2</sub>( $\mu$ -dppb)] (4b)** was prepared from 0.05 mmol of dppb and 0.025 mmol of **1b**. Yield: 50.3 mg, 68%. Anal. Found: C, 44.3; H, 4.1; N, 6.2; S, 4.7%; C<sub>48</sub>H<sub>52</sub>B<sub>2</sub>N<sub>6</sub>O<sub>4</sub>P<sub>2</sub>Ts<sub>2</sub> (1314.84 g mol<sup>-1</sup>) requires C, 43.9; H, 4.0; N, 6.4; S, 4.9%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3394;  $\nu$ (N-H) 3054;  $\nu$ (C=N) 1576;  $\nu$ (B-O) 1333. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ )  $\delta$  7.82–7.75 (m, 6H, PPh<sub>2</sub>), 7.55–7.46 (m, 6H, PPh<sub>2</sub>), 7.39 (dq,  $J = 6.1, 2.5$  Hz, 4H, PPh<sub>2</sub>), 7.36–7.32 (m, 4H, PPh<sub>2</sub>), 7.07 (t,  $J = 3.8$  Hz, 2H, H<sub>5</sub>), 6.96 (d,  $^3J = 7.5$  Hz, 2H, H<sub>2</sub>), 6.33 (s, 4H, B(OH)<sub>2</sub>), 6.10 (s, 2H, NHMe), 2.98 (dd,  $J = 8.6, 4.6$  Hz, 6H, NHMe), 2.40 (d,  $J = 7.8$  Hz, 6H, MeC=N), 2.31–2.17 (m, 4H, PCH<sub>2</sub>), 1.92–1.76 (m, 4H, CH<sub>2</sub>). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone- $d_6$ )  $\delta$  16.04, 15.06, <sup>1</sup>J(PtP) = 3818.23 Hz.

**[(PtL3)<sub>2</sub>( $\mu$ -dppb)] (4c)** was prepared from 0.05 mmol of dppb and 0.025 mmol of **1c**. Yield: 57.1 mg, 78%. Anal. Found: C, 44.9; H, 4.3; N, 6.1; S, 4.6%; C<sub>50</sub>H<sub>56</sub>B<sub>2</sub>N<sub>6</sub>O<sub>4</sub>P<sub>2</sub>Ts<sub>2</sub> (1342.89 g mol<sup>-1</sup>) requires C, 44.7; H, 4.2; N, 6.3; S, 4.8%. IR cm<sup>-1</sup>  $\nu$ (O-H) 3399;  $\nu$ (N-H) 3046;  $\nu$ (C=N) 1572;  $\nu$ (B-O) 1330. <sup>1</sup>H NMR (400 MHz, acetone- $d_6$ )  $\delta$  7.82–7.75 (m, 6H, PPh<sub>2</sub>), 7.55–7.46 (m, 6H, PPh<sub>2</sub>), 7.39 (dt,  $J = 6.1, 2.1$  Hz, 4H, PPh<sub>2</sub>), 7.36–7.32 (m, 4H, PPh<sub>2</sub>), 7.09–7.05 (m, 2H, H<sub>5</sub>), 6.96 (d,  $J = 7.5$



Hz, 2H, H<sub>2</sub>), 6.31 (s, 4H, B(OH)<sub>2</sub>), 6.17 (s, 2H, NH<sub>2</sub>), 3.43 (ddd, *J* = 9.2, 7.1, 5.1 Hz, 4H, CH<sub>2</sub>), 2.40 (d, *J* = 7.1 Hz, 6H, MeC=N), 2.34–2.17 (m, 4H, PCH<sub>2</sub>), 1.94–1.73 (m, 4H, CH<sub>2</sub>), 1.19 (q, <sup>3</sup>*J* = 7.1 Hz, 6H, Me). <sup>31</sup>P-{<sup>1</sup>H} NMR (400 MHz, acetone-*d*<sub>6</sub>) δ 16.06, 15.01, <sup>1</sup>*J*(PtP) = 3821.58 Hz.

The compound synthesis reactions are shown in Scheme 1.

### Cell culture


The HCT116 colorectal cancer cell line and the primary human dermal fibroblasts were obtained from American Type Culture Collection (ATCC®, Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM), while the A2780 carcinoma cell line was acquired from Sigma-Aldrich (Madrid, Spain) and cultured in Roswell Park Memorial Institute (RPMI) medium. Media were supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) of a penicillin/streptomycin solution. The media and supplements were obtained from Thermo Fischer Scientific (Waltham, Massachusetts, USA).

Cells were cultured in 25 cm<sup>2</sup> and/or 75 cm<sup>2</sup> T-flasks in a CO<sub>2</sub> incubator with a humidified atmosphere at 37 °C and 5%

(v/v) CO<sub>2</sub> (SANYO CO<sub>2</sub> Incubator, Electric Biomedical Co., Osaka, Japan).

### Cell viability assays

Cells were initially seeded in 96-well plates at a cell density of 0.75 × 10<sup>5</sup> cells per mL and incubated (37 °C, 5% (v/v) CO<sub>2</sub>) for 24 h. After this period, the media were replaced with fresh media containing the desired compounds (concentrations ranging from 0.1 μM to 50 μM), 0.1% (v/v) of DMSO or 0.4 μM doxorubicin (Dox). After 48 h of incubation under the same conditions, the CellTiter 96® aqueous one solution cell proliferation assay kit (Promega, Madison, USA) was used to evaluate the cell viability by measuring the absorbance at 490 nm in a Tecan Infinite M200 microplate reader (Tecan, Männedorf, Switzerland). Data were analysed with the GraphPad Prism 8 software, where viability-concentration response curves facilitated the calculation of the concentration of compounds that induced a 50% reduction in cell viability (IC<sub>50</sub>).



Scheme 1 Reaction sequence for the synthesis of the reported compounds.



### Complex stability in biological media

The stability of the three platinum compounds (**3a**, **3b** and **3c**) was analysed *via* UV-Visible spectroscopy (Shimadzu Scientific Instruments) with a quartz cuvette (1 cm path length) over a wavelength range of 220–700 nm for three different incubation times, namely 0, 3, 24 and 48 h. Compounds were diluted in RPMI medium without phenol red and FBS after being first dissolved in 100% (v/v) DMSO. Compounds **3a** and **3c** were analysed at a final concentration of 50  $\mu\text{M}$ , while **3b** was analysed at a final concentration of 150  $\mu\text{M}$ .

### ICP-AES (inductively coupled plasma-atomic emission spectrometry)

To evaluate the compound internalization in HCT116 cells, inductively coupled plasma-atomic emission spectroscopy (ICP-AES) was performed. HCT116 cells were seeded in 25  $\text{cm}^2$  T-flasks at a density of  $5 \times 10^5$  cells/T-flask and incubated for 24 h. The culture medium was then replaced with fresh medium with  $10 \times \text{IC}_{50}$  concentrations of the studied compounds or 0.1% (v/v) DMSO, and cells were incubated for 3 h. After this period, the cell culture medium was recovered in a 15 mL Falcon tube and the cells were washed with PBS. After this washing step, the PBS washing solution was also recovered in the 15 mL Falcon tube. Cells were detached from the T-flask with 2 mL of TrypLE Express and centrifuged at 750g (Sigma 3-16K Sartorius, Germany) for 5 min. The supernatant was removed and added to the 15 mL Falcon tube, and the cell pellet was washed 2 more times with PBS. Aqua regia (3 : 1 HCl/HNO<sub>3</sub>) was prepared, and added to the 15 mL Falcon tubes containing the previous washing solutions and the supernatant (non-cellular fraction) or to the cell pellets (cellular fraction). Samples were incubated at room temperature (RT) for 24 h in a hood fume, and then delivered to Laboratório de Análises/LAQV to quantify the platinum levels by ICP-AES.

### Analysis of apoptosis induction by flow cytometry

Apoptosis was evaluated using the Alexa Fluor® 488 Annexin V/dead cell apoptosis kit (Invitrogen, Thermo Fisher Scientific, MA, USA). HCT116 cells were seeded in 6-well plates (at a density of  $2 \times 10^5$  cells per well) for 24 h, and later incubated for 48 h period with the  $\text{IC}_{50}$  concentrations of compounds **3a**, **3b** and **3c**. Cells treated with 0.1% (v/v) DMSO were used as the vehicle control, while cells treated with 0.4  $\mu\text{M}$  Dox were used as positive controls. After 48 h of incubation, cells were washed with PBS and detached from the wells with TrypLE Express (Invitrogen), and then washed again with PBS. Lastly, cells were incubated with the Alexa® Fluor 488-Annexin V solution and 100  $\mu\text{g mL}^{-1}$  of propidium iodide (PI) at RT for 15 min.

Samples were evaluated by the Attune® acoustic focusing flow cytometer (Life Technologies, Carlsbad, USA), and the results were analysed with the Attune® Cytometric software.

### Quantification of BAX and BCL-2 protein levels by western blot

HCT116 cells were cultivated, incubated and collected, as described previously.<sup>32</sup> After collection, cells were submitted to

5 ultrasound pulses on ice (2 min on ultrasound, followed by 30 s on ice; Elma D-78224; Singen/Htw, Germany) and centrifuged at 1000g for 5 min. The total amount of protein in the supernatant extracts was quantified with Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific, Waltham, MA, USA). For SDS-PAGE, 20  $\mu\text{g}$  of protein was loaded on 10% polyacrylamide gel and transferred to a 0.45  $\mu\text{m}$  PVDF membrane (GE Healthcare Life Sciences, Germany) (BAX and BCL-2 proteins). The membrane was blocked for 2 h with 5% (w/v) non-fat milk in TBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween-20), and incubated at room temperature for 1 h under constant agitation with the respective primary antibody solution (anti-BAX, 1 : 5000, Abcam, United Kingdom; and anti BCL-2, 1 : 1000, Sigma, St Louis, MO, USA). After incubation, membranes were washed with TBST buffer three times, for a duration of 5 min each (procedure also repeated after the secondary antibody incubation) and exposed to the secondary antibody solution (1 : 3000, anti-mouse IgG, horseradish peroxidase HPR-linked antibody or 1 : 2000, anti-rabbit IgG, HPR-linked antibody; Cell Signalling Technology, USA). Membranes were treated with the WesternBright ECL substrate (Advanta, USA) for 5 min and later exposed to a film in a dark room. After that, to normalize the results, membranes were incubated two times with stripping buffer (0.1 M glycine, 20 mM magnesium acetate, 50 mM KCl, pH 2.0) for a duration of 10 and 20 min, respectively, and then incubated with anti- $\beta$  actin (1 : 5000; Sigma, St Louis, USA). BAX and BCL-2 protein quantification (densitometry) was performed using the Image J software. BAX and BCL-2 protein levels were normalized to  $\beta$  actin levels.

### Mitochondrial membrane potential ( $\Delta\Psi_m$ ) analysis by flow cytometry

$\Delta\Psi_m$  was analysed using the JC-1 mitochondrial membrane potential assay kit (Abnova Corporation, Walnut, CA, USA). HCT116 cells were seeded in 6-well plates with a density of  $2 \times 10^5$  cells per well, incubated for 24 h, and later incubated for another 48 h period with the  $\text{IC}_{50}$  concentrations of compounds **3a**, **3b** and **3c** or with 0.1% (v/v) DMSO. As positive controls, 0.4  $\mu\text{M}$  Dox and 5  $\mu\text{M}$  Cis were used. After that, cells were washed with PBS, detached with TrypLE Express, and washed with DMEM medium. Cells were then resuspended in DMEM medium without phenol red + 5% (v/v) FBS, and stained with the JC-1 staining solution for 20 min at 37 °C. Lastly, cells were resuspended in DMEM medium without phenol red + 5% (v/v) FBS, and analysed in the Attune® Acoustic Focusing Flow Cytometer (Life Technologies, Carlsbad, CA, USA).

### Caspase-8 activity

HCT116 cells were seeded in 25  $\text{cm}^2$  T-flasks at a density of  $2 \times 10^6$  cells/T-flasks. After 24 h incubation, under the same conditions as described previously, the medium was replaced with fresh medium containing DMSO 0.1% (v/v), 0.4  $\mu\text{M}$  Dox, 5  $\mu\text{M}$  Cis or  $\text{IC}_{50}$  concentrations of the compounds **3a**, **3b** and **3c**, and incubated for 48 h. After that, cells were detached using



cold PBS and a cell scraper, and centrifuged at 500g for 5 min. Then, the instructions provided in the caspase-8 assay kit (Abcam) procedure were followed. Caspase 8 activity was obtained by measuring the absorbance at 400 nm of each sample. Caspase 8 activities were normalized to the corresponding value in DMSO samples.

### Analysis of autophagy by flow cytometry

The autophagic potential of HCT116 cells was evaluated using the autophagy assay kit (ab139484) (Abcam, Cambridge, United Kingdom). HCT116 cells were seeded in 6-well plates with a density of  $2 \times 10^5$  cells per well and incubated for 24 h. After the replacement of the culture medium with fresh medium containing the IC<sub>50</sub> concentrations of compounds **3a**, **3b** and **3c**, cells were incubated for another 48 h. 0.1% (v/v) DMSO, 0.4  $\mu$ M Dox and 5  $\mu$ M Cis were used as controls. In addition, 15 h before finishing the 48 h incubation time, 0.5  $\mu$ M Rapamycin was added to the respective wells. After that, cells were washed with PBS, detached with TrypLE Express, washed with DMEM medium without phenol red + 5% (v/v) FBS, and then incubated with the green stain solution in DMEM medium without phenol red + 5% (v/v) FBS for 30 min at RT. After this period, cells were washed, resuspended in the assay buffer, and then analysed with the Attune® Acoustic Focusing Flow Cytometer (Life Technologies, Carlsbad, CA, USA). The results were analysed with the Attune® Cytometric software.

### Analysis of reactive oxygen species (ROS) production by flow cytometry

HCT116 cells were seeded in 6-well plates at a density of  $2 \times 10^5$  cells per well and incubated for 24 h. The culture medium was replaced with fresh medium containing the IC<sub>50</sub> concentrations of compounds **3a**, **3b** and **3c**, 0.1% (v/v) DMSO, 0.4  $\mu$ M Dox, 5  $\mu$ M cisplatin or 30  $\mu$ M TBHP (positive control as indicated by the manufacturer), and cells were incubated for another 48 h period. Cells were then washed with PBS, detached with TrypLE Express, washed with PBS, and later incubated with 10  $\mu$ M of 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA) (Thermo Fisher Scientific, Waltham, MA, USA) in PBS for 20 min. Cells were later analysed with the Attune® Acoustic Focusing Flow Cytometer (Life Technologies, Carlsbad, USA), and the results were treated with the Attune® Cytometric software.

### Ex ovo CAM assay

The pro-/anti-angiogenic potential of the compounds was evaluated with the *ex ovo* chorioallantoic membrane (CAM) assay, as previously described in (Reigosa-Chamorro *et al.*, 2021<sup>26</sup>),<sup>30,31</sup> Chicken embryos were first incubated for 24 h and later exposed to the IC<sub>50</sub> concentrations of compounds **3a**, **3b** and **3c** dissolved in PBS (in the centre of O-rings) or 0.1% (v/v) DMSO. The compounds' and DMSO's distribution in the embryos were always performed in a different order. Then, embryos were incubated for another 48 h at 37 °C and its images were captured after 0, 24 and 48 h with a digital USB

Microscope Camera (Opti-Tekscope OT-V1) to manually count the newly formed blood vessels *via* ImageJ software. The *ex ovo* CAM assay fulfils the Directive 2010/63/EU of the European Parliament to protect the animal models for scientific purposes.

### Statistical analysis

The presented data are referred to as mean  $\pm$  SEM from at least three biological independent experiments, unless otherwise stated. One-way ANOVA or Student's *t*-test were performed to determine the statistical significance ( $p < 0.05$ ) with the GraphPad Prism 8 software (GraphPad Software, San Diego, CA, USA).

## Results and discussion

The compounds and respective reactions are shown in Scheme 1 for simplification. The thiosemicarbazone ligands **L1–L3**, **a**, **b** and **c** were prepared by reaction of 4-acetylphenylboronic acid with the corresponding thiosemicarbazide as pure air-stable solids, as appropriate (see Experimental section). The NNH proton resonated *ca.* 10.2 ppm, whilst the NH<sub>2</sub> protons, **a**, gave rise to two characteristic resonances in the <sup>1</sup>H NMR spectrum which were attributed to the restricted rotation of the NH<sub>2</sub> group about the C(S)NH<sub>2</sub> bond axis. The NHR protons, **b**, **c**, showed a broad resonance at *ca.*  $\delta$  8.5 ppm. The characteristics of the ligand spectra included two virtual doublets stemming from the aromatic AA'XX' spin system with an *N* value at *ca.* 8.0–7.8 ppm. From them, the new cyclometalated compounds were obtained as described in Scheme 1. The preparative details and characteristic microanalytical and spectroscopic data are given in the Experimental section. Reaction of **a**, **b** or **c**, as appropriate, with potassium tetrachloroplatinate in water/ethanol gave clear solutions. These solutions were used to isolate the tetranuclear compounds **1a–1c** as pure air-stable solids, with the ligand in the *E,Z* configuration. Absence of the NH resonance agreed with deprotonation at the hydrazine group. The <sup>1</sup>H NMR spectra showed the absence of the AA'XX' spin system upon metalation of the *para*-substituted phenyl ring, and distinct resonances were accordingly assigned to the H2, H3 and H5 nuclei (see Experimental).


Reaction of [Pt(**L1–3**)<sub>4</sub> **1a–1c** with tertiary phosphines PPh<sub>3</sub>, Ph<sub>2</sub>PCH<sub>2</sub>PPh<sub>2</sub> (dppm), and Ph<sub>2</sub>P(CH<sub>2</sub>)<sub>4</sub>PPh<sub>2</sub> (dppb), in 1 : 4 or 1 : 2 molar ratios, as appropriate, gave the compounds [Pt(**L1–3**)(PPh<sub>3</sub>)<sub>3</sub>] **2a–2c**, [Pt(**L1–L3**)(Ph<sub>2</sub>PCH<sub>2</sub>PPh<sub>2</sub>-*P*)] **3a–3c**, and [Pt(**L1–L3**)<sub>2</sub>{ $\mu$ -Ph<sub>2</sub>P(CH<sub>2</sub>)<sub>4</sub>PPh<sub>2</sub>}] **4a–4c** as pure air-stable solids (Scheme 1). The microanalytical and spectroscopic data are presented in the Experimental section. The use of excess diphosphine only gave cleavage of the Pt–S<sub>bridging</sub>. Therefore, in compounds with diphosphines, coordination to the metal was only through one phosphorus atom. Usage of excess phosphine did not cleave the Pt–S<sub>chelate</sub> bond. The <sup>1</sup>H NMR spectra showed the high-field shift of the H5 resonance at *ca.* 1 ppm with respect to the corresponding tetranuclear compound,



owing to the shielding effect of the phosphine phenyl rings. The  $^{31}\text{P}$  NMR spectra for the **3a–3c** compounds showed two doublets assigned to the two non-equivalent phosphorus nuclei. The lower field resonance, at *ca.* 12.5 ppm, was assigned to the  $^{31}\text{P}$  nucleus bonded to platinum, in agreement with the  $J(\text{Pt–P})$  values. Meanwhile, for **4a–4c**, the  $^{31}\text{P}$  resonance was a singlet signal in accordance with the existence of equivalent phosphorus nuclei; the chemical shift values were consistent with a phosphorus to nitrogen *trans* geometry.<sup>32,33</sup> The resonance for the ABXY spin system of the  $\text{PCH}_2\text{P}$  protons appeared at *ca.* at  $\delta$  3.52. Attempts to produce mononuclear species analogous to **3a–3c** with diphosphines other than  $\text{Ph}_2\text{PCH}_2\text{PPh}_2$  were unsuccessful.

Suitable crystals of **1b** were grown by slowly evaporating an acetone solution of the complex. The ORTEP illustration of compound **1b** is shown in Fig. 1. The tetranuclear compound crystallizes in the *Pcan* space group with two acetone molecules. Within each molecule, the metalated moieties are displayed as two sets of almost coplanar antiparallel pairs separated at *ca.* 3.5 Å. Each platinum atom of the internal  $\text{Pt}_4\text{S}_4$  nucleus is bonded to a tridentate C,N,S<sub>chelating</sub> ligand and to the sulfur atom, S<sub>bridging</sub>, of another metalated species. The longer Pt–S<sub>chelating</sub> bond lengths, as opposed to Pt–S<sub>chelating</sub>, reflect the differing *trans* influence of the phenyl carbon and nitrogen atoms of the ligands.

Suitable crystals of **2c** were grown by slowly evaporating a chloroform solution of the complex. The crystals were triclinic with  $P\bar{1}$  space group. The ORTEP illustration is shown in Fig. 2. The structure of compound **2c** comprises a molecule




**Fig. 2** ORTEP drawing of the platinumacycle **2c** with thermal ellipsoid plot shown at the 50% probability level. Hydrogen atoms and solvent molecules have been omitted for clarity. Selected bond distances (Å) and angles (°) for 10: Pt(1)–C(6) 2.038(6), Pt(1)–N(1) 2.032(5), Pt(1)–S(1) 2.3558(17), Pt(1)–P(1) 2.2234(18), S(1)–Pt(1)–P(1) 96.97(6), N(1)–Pt(1)–S(1) 83.44(16), N(1)–Pt(1)–P(1) 179.24(18), C(6)–Pt(1)–S(1) 162.95(19), C(6)–Pt(1)–P(1) 99.79(19), and C(6)–Pt(1)–N(1) 79.8(2).

with the platinum(II) atom bonded in a slightly distorted square planar coordination to four different donor atoms, a tridentate thiosemicarbazone through the aryl C(6) carbon, the imine N(1) nitrogen, and the thioamide S(1) sulfur atom, and to a phosphorus atom P(1) of the triphenylphosphine. The bond distances and angles are within the expected values for analogous structures, as was provided by Mogul 2020.3 from the CCDC program package. The angles at platinum are close to 90° with allowance for the somewhat smaller C(6)–Pt(1)–N(1) and S(1)–Pt(1)–N(1) angles, 79.81° and 83.4°, respectively, and larger C(6)–Pt(1)–P(1) and S(1)–Pt(1)–P(1) angles, 99.80° and 96.97°, also respectively, consequent upon chelation. The crystal packing shows the molecules are arranged in sheets held together by means of hydrogen bonding interactions between the boronic acid function, the chlorine atom of the solvent molecule and the amide nitrogen, as well as by  $\pi$ – $\pi$  stacking.

### Antiproliferative activity

The *in vitro* antiproliferative potential of compounds **1a–c**, **2a–c**, **3a–c**, **4a–c** and the respective ligands **a–c** was assessed using the CellTiter 96@Aqueous non-radioactive cell proliferation assay (MTS assay), as described in the Experimental section.<sup>34</sup> This antiproliferative activity was analysed by exposure of the ovarian carcinoma (A2780) and colorectal carcinoma (HCT116) cell lines and normal human primary dermal fibroblasts to 0.1–50  $\mu\text{M}$  of all compounds for 48 h (ESI Fig. S1†). As shown in Fig. S1,† a reduction of the cell viability is observed upon increase of the compounds concentrations. Cell viability-concentration curves (GraphPad software) allowed us to calculate



**Fig. 1** ORTEP drawing of the platinumacycle **1b** with thermal ellipsoid plot shown at the 50% probability level. Hydrogen atoms and solvent molecules are omitted for clarity. Selected bond distances (Å) and angles (°) for 10: Pt(1)–C(11) 2.013(8), Pt(1)–N(10) 1.988(7), Pt(1)–S(3) 2.287(2), Pt(1)–S(4) 2.347(2), S(4)–Pt(1)–S(3) 100.76(8), N(10)–Pt(1)–S(3) 174.5(2), N(10)–Pt(1)–S(4) 84.1(2), C(11)–Pt(1)–S(3) 94.6(3), C(11)–Pt(1)–S(4) 163.9(3), and C(11)–Pt(1)–N(10) 80.8(3).



the relative IC<sub>50</sub> values of each compound for each cell line (Table 1). Moreover, as positive controls, the antiproliferative activity of the Dox and Cis was evaluated through the exposure of A2780, HCT116 and Fibroblast cells to 0.1–50 μM of these antitumor drugs for 48 h (ESI Fig. S2†). The selectivity index (SI) of each compound – the ratio IC<sub>50</sub> in fibroblasts/IC<sub>50</sub> in the tumour cell line – was determined, and it is reported in Table 1 to evaluate the selectivity of the compound towards tumour cell lines. Higher SI values were correlated with higher selectivity of the compound for a particular tumour cell line compared to the normal cells.<sup>35</sup>

Comparing the IC<sub>50</sub> values obtained for the HCT116 cancer cell line for all of the tested compounds (Table 1), compounds **3a–c** presented the lowest IC<sub>50</sub> values (2.1, 1.9 and 8.6 μM, respectively) with the following cytotoxicity order: **3b** > **3a** > **3c**. Moreover, A2780 cells compounds **3a–c** also presented the lowest IC<sub>50</sub> values (5.0, 1.9, 8.0, respectively), maintaining the same cytotoxicity order of **3b** > **3a** > **3c** (Table 1). Interestingly, in the HCT116 cells, these 3 compounds presented a higher cytotoxic potential when compared to the chemotherapeutic agent, cisplatin (IC<sub>50</sub> value of 15.6 μM). All the other compounds do not demonstrate cytotoxicity in the HCT116 colorectal carcinoma cell line (IC<sub>50</sub> > 50 μM). This clearly indicates that coordination with dppm – Ph<sub>2</sub>PCH<sub>2</sub>PPh<sub>2</sub>-P provides a higher cytotoxicity compared to the other phosphines (PPh<sub>3</sub> or dppb) (Table 1).

In A2780 ovarian carcinoma cells, compounds **1a–c**, **2b**, and **4a–c** show moderate cytotoxicity values (10 μM < IC<sub>50</sub> < 50 μM) (Table 1). Among all compounds, it seems that compounds with substitution **b** (R=Me) show more cytotoxic effects, although ligands **1**, **2** and **3** did not present any cytotoxicity when tested separately (Table 1). We have yet to find a plausible explanation for the differing values for compounds **3a**, **3b** as compared to **3c**. The modification of the –NHR group was not thought to have a significant effect on the modes of action of the compounds, but more in the fine-tuning of internalization and their properties. It is possible that R groups with longer carbon chains affect interactions with the biological membranes and/or targets. This puts forward the need to examine distinct options when designing a metallodrug.

One of the main reasons and interest to develop new platinum-based compounds is to circumvent the high cytotoxicity of approved platinum drugs, and to reduce the side effects in healthy tissues. Therefore, it is important that compounds **3a–c** have much higher IC<sub>50</sub> values in a normal human cell line when compared to the values obtained for the studied tumor cell lines. Fibroblasts were used as healthy cells due to their importance in the tumor microenvironment,<sup>36</sup> and the IC<sub>50</sub> values obtained are reported in Table 1.

Interestingly, when analysing the IC<sub>50</sub> values obtained for fibroblasts (Table 1), all of the compounds showed low cytotoxic potential (IC<sub>50</sub> values >50 μM), which is reflected in the high SI values. At the limit, if we consider the IC<sub>50</sub> of compounds **3a–c** in fibroblasts as equal to 50 μM, compounds **3a** and **3b** showed the highest SI values (23.8 and 26.3, respectively) in the HCT116 cancer cell line, meaning that those com-

**Table 1** Relative IC<sub>50</sub> values and SI obtained for each of the platinum compounds and respective ligands in HCT116, A2780 and fibroblast cell lines. IC<sub>50</sub> values are expressed as the mean ± SEM of at least three biological independent assays

Complex	Cell line	IC <sub>50</sub> (μM)	SI
<b>1a</b>	HCT116	>50	—
	A2780	10 < IC <sub>50</sub> < 50	—
	Fibroblasts	>50	—
<b>1b</b>	HCT116	>50	—
	A2780	35.7	>1.4
	Fibroblasts	>50	—
<b>1c</b>	HCT116	>50	—
	A2780	10 < IC <sub>50</sub> < 50	—
	Fibroblasts	>50	—
<b>2a</b>	HCT116	>50	—
	A2780	>50	—
	Fibroblasts	>50	—
<b>2b</b>	HCT116	>50	—
	A2780	31.9	>1.6
	Fibroblasts	>50	—
<b>2c</b>	HCT116	>50	—
	A2780	>50	—
	Fibroblasts	>50	—
<b>3a</b>	HCT116	2.1	>23.8
	A2780	5.0	>10
	Fibroblasts	>50	—
<b>3b</b>	HCT116	1.9	>26.3
	A2780	1.9	>26.3
	Fibroblasts	>50	—
<b>3c</b>	HCT116	8.6	>5.8
	A2780	8.0	>6.3
	Fibroblasts	>50	—
<b>4a</b>	HCT116	>50	—
	A2780	10 < IC <sub>50</sub> < 50	—
	Fibroblasts	>50	—
<b>4b</b>	HCT116	>50	—
	A2780	31.0	>1.6
	Fibroblasts	>50	—
<b>4c</b>	HCT116	>50	—
	A2780	10 < IC <sub>50</sub> < 50	—
	Fibroblasts	>50	—
<b>L1</b>	HCT116	>50	—
	A2780	>50	—
	Fibroblasts	>50	—
<b>L2</b>	HCT116	>50	—
	A2780	>50	—
	Fibroblasts	>50	—
<b>L3</b>	HCT116	>50	—
	A2780	>50	—
	Fibroblasts	>50	—
Doxorubicin (Dox)	HCT116	0.5 ± 0.10	24.2
	A2780	0.1 ± 0.04	121
	Fibroblasts	12.1 ± 0.20	—
Cisplatin (Cis)	HCT116	15.6 ± 5.30	0.6
	A2780	1.9 ± 0.20	4.6
	Fibroblasts	8.8 ± 2.90	—

> indicates that the IC<sub>50</sub> is higher than the value indicated; – SI values not calculated.




pounds are at least 23.8× more cytotoxic for HCT116 cancer cells than for fibroblasts. Considering the same approach, compounds **3a** and **3b** also show higher SI values in the A2780 cancer cell line (10 and 26.3, respectively). Compound **3c** presented a SI value of 5.8 in the HCT116 cell line, and a slightly higher SI value (6.3) for the A2780 cell line. It is also interesting to note that all of the ligands (**a**, **b** and **c**) do not show a cytotoxic effect in the tested cell lines ( $IC_{50} > 50 \mu\text{M}$  in tumor and normal cells). Interestingly, our previous data<sup>37</sup> show high cytotoxicity for the free  $\text{PPh}_3$  (a ligand that is present in compounds **2a**, **2b** and **2c**) and for other free diphenylphosphines in normal fibroblasts. In the present work, we show a high cytotoxicity for compounds, particularly those harbouring dppm, in tumor cell lines and no cytotoxicity in fibroblasts. This means that this effect is probably attributed to the effects of the compounds *per se*, and not of the free ligands, even though free phosphines also have high cytotoxicity in these tumor cell lines.<sup>37</sup> Thus, compounds **3a**, **3b** and **3c** show an overall very good therapeutic window and potential in the HCT116 cell line and from now on, all of the remaining stability and biological analysis will be assessed for these 3 compounds in the HCT116 cell line.

### Complex stability in biological media

After selection of the best compounds for pursuing additional biological characterization, the stability of the compound (**3a**, **3b** and **3c**) in biological medium was analyzed using UV-Visible spectroscopy over a wavelength range of 220 to 700 nm for different incubation times (–0, 3 h, as shown in Fig. 3; 0, 24, 48 h in ESI Fig. S5†).

Analysing the spectra of all compounds, high-energy absorption bands corresponding to  $\pi \rightarrow \pi^*$  and  $n \rightarrow \pi^*$  transitions with peaks in the 230–330 and 330–400 nm ranges, respectively, that are associated with the aromatic rings of terpyridines can be observed.<sup>38</sup> According to Fig. 3, for compound **3a**, bands are observed at approximately 235 nm, 265 nm and 360 nm at 0 h. For compound **3b**, four characteristic bands can be identified at approximately 293, 325, 352 and 371 nm. Finally, compound **3c** presents bands at approximately 235 nm, 265 nm, 327 nm, 365 nm, 380 nm and 530 nm. As observed in Fig. 3, from 0 h to 3 h, there is an increase of absorbance that is most probably due to a better solubilization of the complexes in the medium, maintaining their characteristic bands. However, analysing the data from ESI Fig. S5,† it is possible to observe a change in the peak at 265 nm to 272 nm from 0 h to 48 h for compound **3c**. However, for **3a** at 24 h, the band at 360 nm is no longer observed. Furthermore, at 48 h there is a peak at approximately 325 nm, which may indicate that the complex is not stable in solution (ESI Fig. S5†). Furthermore, there is not a large decrease in the absorbance values throughout the spectrum between the different acquisition times. Regarding compound **3b**, the four characteristic bands remained at the same wavelength throughout the 48 h. However, between 0 h and 24 h, there is a slight decrease in all absorbances throughout the spectrum (ESI Fig. S5†).



**Fig. 3** Evaluation of the stability of compounds **3a** (A), **3b** (B) and **3c** (C) via UV-visible spectroscopy for 3 h. Absorbance spectra of 50  $\mu\text{M}$  of compounds **3c** and **3a** and 150  $\mu\text{M}$  **3b** in an RPMI medium without phenol red and FBS at different incubation times: 0 h (orange) and 3 h (blue).

Considering the stability of all compounds during the first three hours, we further accessed their internalization in HCT116 cells in this period. Nevertheless, for ensuring the best solubility and stability of the compounds in all biological assays, they were always performed with freshly prepared solutions of these compounds.

### Compound cellular internalization by ICP-AES

The internalization of the platinum compounds **3a**, **3b** and **3c** in HCT116 cells was evaluated by ICP-AES technique, which allows a quantitative measurement of the amount of metal present in each sample. This assay allows us to understand if the compounds under study are indeed internalized by HCT116 cells.<sup>39</sup> To perform this technique, HCT116 cells were



exposed to 10× the IC<sub>50</sub> values of each platinum compounds for 3 h.

The obtained results showed an internalization of almost 100% for all compounds after 3 h, with compound **3c** being the one with a higher percentage of internalization (97.3 ± 0.2%), followed by compound **3b** (96.5 ± 0.3%) and ultimately compound **3a** (95.7 ± 0.1%). Considering this, the compounds are stable and soluble in biological medium by the time they are internalized in HCT116 cells (Fig. 3).

### Cell death by apoptosis and/or necrosis


As the platinum compounds can induce a decrease in HCT116 cell viability, it is important to understand the type of cell death that is been triggered by their presence. Thus, the levels of apoptosis (a programmed cell death mechanism) and necrosis (a non-programmed cell death mechanism) after the exposure of HCT116 cells for 48 h to compounds **3a–c** (at their IC<sub>50</sub> concentrations) were measured through flow cytometry using Annexin V-Alexa fluor 488/PI double staining (Fig. 4). 0.1% DMSO (v/v) was used as the vehicle control (negative control) and Dox (0.4 μM) was used as the positive control.

Annexin V has a high affinity for phosphatidylserine, which is present on the inner surface of the lipid bilayer of plasma membranes in viable cells. Once cells initiate the apoptotic process, phosphatidylserine is translocated to the outer layer of the membrane, favouring the interaction between annexin V and phosphatidylserine and the identification of cells in apoptosis by flow cytometry.<sup>39–41</sup> Furthermore, PI (a fluorescent molecule that is impermeable to membranes in viable cells) allows for the detection of cells with a compromised membrane – cells in necrosis.<sup>40,42</sup> Therefore, this method allows for distinguishing between cells in early apoptosis (labelled with annexin V-Alexa fluor 488), cells in late apoptosis (labelled with both annexin V-Alexa fluor 488 and PI), and cells in necrosis (labelled with PI) from normal viable cells (not labelled).<sup>40,42</sup> The results shown in Fig. 4 indicate that the HCT116 cells exposed to compound **3c** present the highest per-


centage of apoptosis (40.3%), while cells exposed to compounds **3a** and **3b** present about 30% apoptosis. On the contrary, cells exposed to DMSO presented 75.1% viable cells, 24.3% apoptosis and 0.6% necrosis. The exposure of the cells to Dox leads to cell values of 40% in apoptosis and 20.2% in necrosis. These results are in agreement with that previously observed in the literature.<sup>43</sup>

Comparing the results obtained for each complex to those obtained for DMSO, compound **3c** shows a significant increase of 1.7× of the percentage of cells in apoptosis, while compounds **3a** and **3b** show an increase of 1.2× of the percentage of cells in apoptosis. Therefore, the platinum compounds induce apoptosis in HCT116 cells in levels that are relatively close to those exhibited in the presence of the positive control, Dox (Fig. 4). Fig. 4 also reveals that the percentage of necrotic cells was low under all analysed conditions, except for HCT116 cells exposed to Dox (~20%), a result that correlates with the literature.<sup>44,45</sup> This result is highly relevant as necrosis is a non-programmed cell death mechanism that is usually associated with the trigger of inflammation, a process that is not ideal in a tumor context.<sup>44,45</sup> It is interesting to note that compound **3c** has a slightly higher internalization by ICP-AES after 3 h, which correlates with its higher level of apoptosis (Fig. 4).

To evaluate whether the platinum compounds could induce apoptosis by the intrinsic pathway, the expression of BAX and BCL-2, a pro-apoptotic and an anti-apoptotic protein, respectively, was analysed in HCT116 cells after 48 h of exposure to the IC<sub>50</sub> of each compound (Fig. 5). Usually, a BAX/BCL-2 ratio of >1 indicates that cell death by apoptosis is promoted. Conversely, a ratio lower than 1 results in cell survival. Thus, the balance of these two proteins is an important factor to determine the cell fate.<sup>46,47</sup>



**Fig. 4** Apoptosis induction in HCT116 cells exposed to the IC<sub>50</sub> of the compounds **3a–c** for 48 h via flow cytometry using Annexin V/PI double staining. DMSO 0.1% (v/v) was used as a negative control (vehicle control) and Dox (0.4 μM) as a positive control. Data are expressed as mean ± SD of at least two independent assays. The symbols \*\*\*\*, \*\*\* and \* represent  $p < 0.0001$ ,  $p < 0.001$  and  $p < 0.1$ , respectively.



**Fig. 5** Relative expression of BAX (A) and BCL-2 (B) proteins in HCT116 cells after 48 h exposure to the IC<sub>50</sub> of compounds **3a**, **3b** and **3c** or 0.1% DMSO (vehicle control). (C) BAX/BCL-2 ratio. (D) Western blot bands used for quantification of BAX and BCL-2 proteins. Data were normalized to the DMSO vehicle control (value of 1 is represented with a dotted line) after an initial normalization with β-actin. Results are expressed as the mean ± SEM of two independent assays. The symbols \*\*\*\* and \*\* represent  $p < 0.0001$  and  $p < 0.01$ , respectively.




An increase of the expression of BAX protein when HCT116 cells are exposed to compounds **3b** and **3c**, compared to the levels shown by the control, is accompanied by a decrease of the expression of the BCL-2 protein (Fig. 5A and B). On the contrary, cells exposed to compound **3a** have the same levels of expression of the BAX and BCL-2 proteins when compared to the DMSO control. The BAX/BCL-2 ratio (Fig. 5C) shows that compounds **3b** and **3c** have a 2.6-fold or 4-fold increase over the control, respectively, an indication that they can trigger the intrinsic/mitochondrial apoptotic pathway in the HCT116 cell line. On the contrary, compound **3a** exhibits a BAX/BCL-2 ratio that is near 1, which suggests that this compound does not seem to induce an apoptotic pathway that is dependent on the expression of BAX. Nevertheless, as we have demonstrated, compound **3a** induces apoptosis (Fig. 4) without other alternative pathways, such as the extrinsic apoptotic pathway or an intrinsic pathway that is dependent on BAK or other pro-apoptotic protein.

To further confirm that compounds **3b** and **3c** can induce the intrinsic apoptotic pathway, their effect in disrupting the mitochondrial membrane potential ( $\Delta\Psi_m$ ) should also be analysed.

#### Evaluation of the mitochondrial membrane potential ( $\Delta\Psi_m$ )

The induction of the intrinsic/mitochondrial pathway of apoptosis correlates with changes in the mitochondrial membrane potential.<sup>48,49</sup> In this regard, it is essential to study the effect of the compounds in the mitochondria and in its membrane potential. The cationic dye JC-1 has been widely used to evaluate the integrity/changes in the mitochondrial membrane potential.<sup>49,50</sup> This dye naturally accumulates within the mitochondria due to its cationic properties, which enables the formation of aggregates that show a red fluorescence (from 532 to 590 nm).<sup>49,50</sup> When the inner mitochondrial membrane is compromised and has a negative potential (high  $\Delta\Psi_m$ ), the JC-1 dye will leave the mitochondria, accumulating in the cytosol in the monomeric form, which changes the dye's fluorescence to green (from 510 to 560 nm).<sup>49,50</sup> Therefore, cells with depolarized mitochondria will display a lower red/green fluorescence ratio. The HCT116 cell line was exposed to the IC<sub>50</sub> concentrations of each platinum compound for 48 h, and the red/green fluorescence ratios were obtained and are represented in Fig. 6.

The results presented in Fig. 6 show that all of the compounds promote significant changes in the mitochondrial membrane when compared to the DMSO control. Compound **3b** affects the mitochondrial membrane the most, with a JC-1 ratio of 0.69. According to the previous results (Fig. 5), exposure of the cells to compounds **3b** and **3c** promote a loss of  $\Delta\Psi_m$  and permeability occurs, which leads to the release of mitochondria proteins (e.g., cytochrome C) into the cytosol, and activation of the intrinsic apoptosis pathway (Fig. 6). Compound **3a** has previously been shown to induce apoptosis (Fig. 4) and a disruption of the mitochondrial membrane potential (Fig. 6), which is not in line with the results obtained for the expression of BAX and BCL-2 protein since their ratio



**Fig. 6** Evaluation of the mitochondrial membrane potential of HCT116 cells exposed for 48 h to the IC<sub>50</sub> concentrations of the compounds **3a–c** via flow cytometry. 0.1% (v/v) DMSO was used as the vehicle control, and 5 μM Cis and 0.4 μM Dox were used as positive controls. Data are normalized to the control of DMSO and expressed as the mean ± SEM of at least two independent biological assays. The symbols \*\* and \* represent  $p < 0.0001$  and  $p < 0.01$ , respectively.

was only slightly above 1 (1.27) (Fig. 5). This indicates that the depolarization of the mitochondria membrane potential is probably dependent on a different pro-apoptotic protein (e.g., BAK), or via an alternative extrinsic pathway involving t-BID.<sup>51,52</sup> The extrinsic apoptotic pathway is usually activated through external signals recognized by death receptors at the cell membrane. This triggers activation of caspase-8 that may cleave BID into t-BID.<sup>52,53</sup> Compound **3a** may also directly affect the mitochondria, as described previously in the literature.<sup>53</sup>

#### Evaluation of caspase-8 activity


As explained above, external signals recognized by the death cellular receptors are able to trigger caspase 8, which can induce the cleavage of several molecules, such as t-BID, mitochondrial or nuclear proteins, or directly downstream caspases.<sup>52</sup> The chromogenic substrate IEDT-pNA, which is constituted by the IETD (Ile-Glu-Thr-Asp) peptide conjugated with the chromophore *p*-nitroanilide (pNA), is usually used as a way to quantify the caspase 8 activity of the total protein extracts.<sup>54</sup> When the substrate is cleaved by caspase 8, the pNA is released, which can be quantified by measuring the absorbance at 400 nm.<sup>55</sup> To evaluate caspase 8 activity induced by the compounds, HCT116 cells were incubated for 48 h with the IC<sub>50</sub> concentration of compound **3a** (Fig. 7).

Analysing the data presented in Fig. 7, exposure of the HCT116 cells to compound **3a** or Cis leads to an increase of caspase-8 activity when compared to the DMSO control (4× and 6× higher, respectively). These data agree with previous results (Fig. 5 and 6), and confirm that compound **3a** can induce cell death via the extrinsic apoptotic pathway.

#### Evaluation of autophagy induction

Besides apoptosis, there are other different types of programmed cell death, such as autophagy, that are commonly triggered by different metal compounds.<sup>56</sup> Autophagy is associ-






**Fig. 7** Caspase-8 activity in HCT116 cells exposed to the IC<sub>50</sub> of compound **3a** for 48 h. 0.1% (v/v) DMSO was used as the vehicle control and 5 μM Cis as positive control. Caspase 8 activity was quantified using the caspase 8 assay kit (Abcam). Data are normalized to the control of DMSO (value represented with a dotted line) and expressed as the mean ± SEM of at least two independent biological assays. The symbols \*\* and \* represent  $p < 0.0001$  and  $p < 0.001$ , respectively.

ated with an increase in autophagosomes (which are intracellular double membrane vesicles) that can fuse with lysosomes, resulting in cellular material degradation.<sup>57</sup> Therefore, the induction of autophagy in HCT116 cells after 48 h of exposure to IC<sub>50</sub> concentrations of the compounds **3a–c** was evaluated (Fig. 8).

Fig. 8 shows that compound **3c**, Dox and Cis can induce the autophagic process in HCT116 cells (77.1%, 61.3% and 65.2% of cells in autophagy, respectively), demonstrating 1.6-, 1.3- and 1.4-fold increase of autophagic vesicles over the control, respectively. Compounds **3a** and **3b** do not seem to induce this type of cell death mechanism. These results indicate that compound **3c** can activate both cell death mechanisms through activation of the apoptosis and autophagy in HCT116 cells. These results are supported by the literature, where it is described that platinum compounds can induce apoptosis and autophagy.<sup>56</sup>

To further understand the triggering process of those cell death processes and loss of viability by the presence of the platinum compounds, the levels of intracellular reactive oxygen species (ROS) were measured.<sup>58</sup>



**Fig. 8** Induction of autophagy in HCT116 cells after 48 h of exposure to the IC<sub>50</sub> of compounds **3a**, **3b** and **3c**. 0.1% (v/v) DMSO was used as the vehicle control, while 5 μM Cis, 0.4 μM Dox and 500 nM Rapamycin were used as positive controls. Data are expressed as the mean ± SEM of at least two independent biological assays. The symbols \*\*\*, \*\* and \* represent  $p < 0.0001$ ,  $p < 0.01$  and  $p < 0.1$ , respectively.

### Production of reactive oxygen species (ROS)

The level of intracellular ROS was quantified in HCT116 cells after their exposure to the platinum compounds (Fig. 9) using the probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-DA). This probe can diffuse into the cells, and once inside, can be deacetylated by intracellular esterases and oxidized by ROS, originating from the fluorescent molecule 2',7'-dichlorofluorescein (DCF), which can be detected by flow cytometry.<sup>58</sup>


The results shown in Fig. 9 indicate that the compounds **3a** and **3b** can trigger ROS production in HCT116 cells, with a respective increase by 1.5-fold and 1.8-fold, over the DMSO control, with these values being close to the positive control TBHP (1.6× higher than the DMSO control). Intracellular ROS production by HCT116 cells in the presence of compounds **3a** and **3b** may lead to the activation of cell death by apoptosis.<sup>59,60</sup> Induction of ROS production by the action of the platinum compounds has been described previously in the literature.<sup>61</sup> Compound **3c** does not seem to induce ROS production (Fig. 9).

### Ex ovo chorioallantoic membrane (CAM) *in vivo* assay

The angiogenesis process, which consists of the formation of new blood vessels, has a determinant role in the tumor development, since it increases the nutrition of cancer cells and enables the invasion of adjacent tissues.<sup>62,63</sup> Therefore, it is important to understand the role of new compounds in this process to achieve better cancer treatment.<sup>64</sup>


The *ex ovo* chorioallantoic membrane (CAM) assay is a great *in vivo* model to evaluate the cytotoxicity of different compounds and their potentiality to modulate angiogenesis, being pro-angiogenic or anti-angiogenic. In this regards, CAMs of chicken embryos were treated with the IC<sub>50</sub> concentrations of compounds **3a–c** for 48 h. All newly formed vessels were counted at different time points (0 h (control), 24 h and 48 h) after exposure, and then compared with the formed vessels for DMSO 0.1% vehicle controls (Fig. 10).

Based on Fig. 10, exposure to all compounds lead to a reduction of the newly formed blood vessels, indications that



**Fig. 9** ROS produced by HCT116 cells after 48 h of exposure to the IC<sub>50</sub> of compounds **3a–c**. 0.1% (v/v) DMSO was used as the vehicle control, and 30 μM TBHP (*tert*-butyl hydroperoxide), 5 μM Cis and 0.4 μM Dox were used as positive controls. Data were normalized against the DMSO control (value represented as a dot line at  $y = 1$ ) and expressed as the mean ± SEM of two independent assays. The symbols \*\*\*, \*\* and \* represent  $p < 0.0001$ ,  $p < 0.01$  and  $p < 0.1$ , respectively.





**Fig. 10** Newly formed blood vessels after exposure of chick embryos to the  $IC_{50}$  of compounds **3a–c** for a duration of 48 h. (A) RGB image of the O-ring interior; (B) green channel of the same image used for counting the number of veins; (C) binary of the segmented image used to calculate the number of branches; (D) percentage of newly formed vessels in *ex ovo* YSMs after 24 h and 48 h exposure to  $IC_{50}$  concentrations of compounds **3a–c**. At least 7 independent chicken embryos experiments were used for each condition. The values were normalized to the number of tertiary veins obtained after exposure to the control (0.1% DMSO) and the number of tertiary veins obtained in the corresponding o-ring at 0 hours of incubation in the same embryo. The 100% value refers to the 0.1% (v/v) DMSO sample in PBS. Symbols: dots – 24 hours, triangles – 48 h. The symbols \*\* and \* represent  $p < 0.01$  and  $p < 0.1$ , respectively.

are in line with their anti-angiogenic potential at their  $IC_{50}$  concentrations.

Importantly, after 48 h of exposure to the  $IC_{50}$  concentration of these three platinum compounds, no *in vivo* toxicity to embryos were observed, considering their survival throughout the duration of the assay.

## Conclusions

The study of the different structures synthesized in this work reveals a trend in the anticancer effect of the series. While the metallated compounds show differing levels of cytotoxicity, the tested ligands **a**, **b** and **c** do not show cytotoxicity in the tested tumor cell lines, disclosing that the observed cytotoxicity for the platinum compounds might not be attributed to them. However, the effect of the ancillary ligands was far greater than the substitution of the amine group. Among all studied compounds, the ones bearing dppm stood out for their high cytotoxicity in HCT116 and A2780 cancer cell lines. Moreover, compounds **3a**, **3b** and **3c** do not show cytotoxicity in normal cells (fibroblasts), which is in line with their high selectivity index towards cancer cells when compared to normal cells (fibroblasts). All compounds were able to induce apoptosis *via* a

depolarization of the mitochondria membrane potential. In the case of compound **3a**, this is triggered *via* an extrinsic mechanism (probably associated with t-BIB). Conversely, compounds **3b** and **3c** can induce mitochondrial or intrinsic apoptosis *via* BAX. Moreover, compound **3c** is able to induce cell death by autophagy. Compounds **3a** and **3b** are able to induce intracellular ROS, which might be associated with the loss of cell viability and cell death. It is also worth mentioning that these compounds are shown to be non-toxic *in vivo* in an *ex ovo* CAM model, although they show an anti-angiogenic potential after exposure to the  $IC_{50}$  of compounds **3a**, **3b** and **3c**.

## Data availability

All the data are available within the manuscript and ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work is financed by national funds from FCT - Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project DOI: [10.54499/UIBP/04378/2020](https://doi.org/10.54499/UIBP/04378/2020) and DOI: [10.54499/UIDB/04378/2020](https://doi.org/10.54499/UIDB/04378/2020) of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project DOI: [10.54499/LA/P/0140/2020](https://doi.org/10.54499/LA/P/0140/2020) of the Associate Laboratory Institute for Health and Bioeconomy - i4HB and doctoral grant 2021.08629.BD (S. Cordeiro). We thank Tatiana Fernandes for her help in performing the stability spectral measurements and western blot assay.

This work was also made possible thanks to the financial support received from the Xunta de Galicia (Galicia, Spain) under the Grupos de Referencia Competitiva Programme (project GRC2019/14). F. R. thanks the Spanish Ministry of Education (grant FPU15/07145).

## References

- A. C. Cope and R. W. Siekman, Formation of Covalent Bonds from Platinum or Palladium to Carbon by Direct Substitution, *J. Am. Chem. Soc.*, 1965, **87**(14), 3272–3273, DOI: [10.1021/ja01092a063](https://doi.org/10.1021/ja01092a063).
- R. Ujjval, M. Deepa, J. M. Thomas, C. Sivasankar and N. Thirupathi, Unusual  $[Pt\{\kappa_2(C,N)\}]^+ \rightarrow [Pt\{\kappa_2(N,N)\}]^+$  Coordination Mode Flip of the Guanidinate(1-) Ligand in Cationic N,N',N''-Tris(3,5-Xylyl)Guanidinatoplatinum(II) Bis (Phosphine) Complexes. Syntheses, Structural and Theoretical Studies, *Organometallics*, 2020, **39**(20), 3663–3678, DOI: [10.1021/acs.organomet.0c00408](https://doi.org/10.1021/acs.organomet.0c00408).
- A. I. D'Aquino, H. F. Cheng, J. Barroso-Flores, Z. S. Kean, J. Mendez-Arroyo, C. M. McGuirk and C. A. Mirkin, An Allosterically Regulated, Four-State Macrocyclic, *Inorg.*



- Chem.*, 2018, **57**(7), 3568–3578, DOI: [10.1021/acs.inorgchem.7b02745](https://doi.org/10.1021/acs.inorgchem.7b02745).
- 4 M. E. Moustafa, P. D. Boyle and R. J. Puddephatt, Reactivity and Mechanism in Reactions of Methylene Halides with Cycloneophylplatinum(II) Complexes: Oxidative Addition and Methylene Insertion, *J. Organomet. Chem.*, 2021, **941**, 121083, DOI: [10.1016/j.jorganchem.2021.121803](https://doi.org/10.1016/j.jorganchem.2021.121803).
  - 5 A. Ionescu, N. Godbert, A. Crispini, R. Termine, A. Golemme and M. Ghedini, Photoconductive Nile Red Cyclopalladated Metallomesogens, *J. Mater. Chem.*, 2012, **22**(44), 23617–23626, DOI: [10.1039/c2jm34946a](https://doi.org/10.1039/c2jm34946a).
  - 6 M. Iliş, M. Micutz and V. Cîrcu, Luminescent Palladium(II) Metallomesogens Based on Cyclometalated Schiff Bases and N-Benzoyl Thiourea Derivatives as Co-Ligands, *J. Organomet. Chem.*, 2017, **836–837**, 81–89, DOI: [10.1016/j.jorganchem.2017.03.015](https://doi.org/10.1016/j.jorganchem.2017.03.015).
  - 7 Á. Vivancos, D. Bautista and P. González-Herrero, Phosphorescent Tris-Cyclometalated Pt(IV) Complexes with Mesoionic N-Heterocyclic Carbene and 2-Arylpyridine Ligands, *Inorg. Chem.*, 2022, **61**(30), 12033–12042, DOI: [10.1021/acs.inorgchem.2c02039](https://doi.org/10.1021/acs.inorgchem.2c02039).
  - 8 H. Torralvo, J. Albert, X. Ariza, M. Font-Bardia, J. Garcia, J. Granell and M. Martinez, Pyridine- A Nd Quinoline-Derived Imines as N, N-Bidentate Directing Groups in Palladium versus Platinum C-H Bond Activation Reactions, *Organometallics*, 2021, **40**(2), 203–217, DOI: [10.1021/acs.organomet.0c00703](https://doi.org/10.1021/acs.organomet.0c00703).
  - 9 H. Takahashi and J. Tsuji, Organic Syntheses by Means of Noble Metal Compounds: XXXIII. Carbonylation of Azobenzene-Palladium Chloride Complexes, *J. Organomet. Chem.*, 1967, **10**(3), 511–517.
  - 10 J. Vicente, I. Saura-Llamas, J. Turpin, D. Bautista, C. R. De Arellano and P. G. Jones, Insertion of One, Two, and Three Molecules of Alkyne into the Pd-C Bond of Ortho-Palladated Primary and Secondary Arylalkylamines, *Organometallics*, 2009, **28**(14), 4175–4195, DOI: [10.1021/om9002895](https://doi.org/10.1021/om9002895).
  - 11 W. A. Herrmann, C. Brossmer, K. Öfele, C.-P. Reisinger, T. Priermeier, M. Beller and H. Fischer, Palladacycles as Structurally Defined Catalysts for the Heck Olefination of Chloro- and Bromoarenes, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**(17), 1844–1848, DOI: [10.1002/anie.199518441](https://doi.org/10.1002/anie.199518441).
  - 12 M. Beller, H. Fischer, W. A. Herrmann, K. Öfele and C. Brossmer, Palladacycles as Efficient Catalysts for Aryl Coupling Reactions, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**(17), 1848–1849.
  - 13 W. A. Herrmann, V. P. W. Böhm and C.-P. Reisinger, Application of Palladacycles in Heck Type Reactions, *J. Organomet. Chem.*, 1999, **576**(1), 23–41.
  - 14 N. Miyaura and A. Suzuki, Stereoselective Synthesis of Arylated (E)-Alkenes by the Reaction of Alk-1-Enylboranes with Aryl Halides in the Presence of Palladium Catalyst, *J. Chem. Soc., Chem. Commun.*, 1979, **19**, 866–867.
  - 15 A. Suzuki, Carbon–Carbon Bonding Made Easy, *Chem. Commun.*, 2005, **18**, 4759–4763.
  - 16 F. Lucio-Martínez, L. A. Adrio, P. Polo-Ces, J. M. Ortigueira, J. J. Fernández, H. Adams, M. T. Pereira and J. M. Vila, Palladacycle Catalysis: An Innovation to the Suzuki–Miyaura Cross-Coupling Reaction, *Dalton Trans.*, 2016, **45**(44), 17598–17601, DOI: [10.1039/c6dt03542f](https://doi.org/10.1039/c6dt03542f).
  - 17 H. Qian, T. Zhang, L. Song, S. Yu, Q. Yuan, L. Sun, D. Zhang, Z. Yin and Y. Dai, Di- and Tetranuclear Palladium(II) Complexes Containing C,N-Bidentate Furoylhydrazone for Suzuki–Miyaura Reactions, *Eur. J. Org. Chem.*, 2017, **10**, 1337–1342, DOI: [10.1002/ejoc.201700027](https://doi.org/10.1002/ejoc.201700027).
  - 18 W. C. Wang, K. F. Peng, M. T. Chen and C. T. Chen, Palladacycles Bearing Tridentate CNS-Type Benzamidinate Ligands as Catalysts for Cross-Coupling Reactions, *Dalton Trans.*, 2012, **41**(10), 3022–3029, DOI: [10.1039/c2dt11097k](https://doi.org/10.1039/c2dt11097k).
  - 19 S. Ramírez-Rave, D. Morales-Morales and J. M. Grévy, Microwave Assisted Suzuki–Miyaura and Mizoroki–Heck Cross-Couplings Catalyzed by Non-Symmetric Pd(II) CNS Pincers Supported by Iminophosphorane Ligands, *Inorg. Chim. Acta*, 2017, **462**, 249–255, DOI: [10.1016/j.ica.2017.03.044](https://doi.org/10.1016/j.ica.2017.03.044).
  - 20 D. A. Alonso, C. Nájera and M. C. Pacheco, Oxime-Derived Palladium Complexes as Very Efficient Catalysts for the Heck–Mizoroki Reaction, *Adv. Synth. Catal.*, 2002, **344**(2), 172–183, DOI: [10.1002/1615-4169\(200202\)344:2<172::AID-ADSC172>3.0.CO;2-9](https://doi.org/10.1002/1615-4169(200202)344:2<172::AID-ADSC172>3.0.CO;2-9).
  - 21 C. Navarro-Ranninger, I. López-Solera, V. M. González, J. M. Pérez, A. Alvarez-Valdés, A. Martín, P. R. Raithby, J. R. Masaguer and C. Alonso, Cyclometalated Complexes of Platinum and Palladium with N-(4-Chlorophenyl)- $\alpha$ -Benzoylbenzylideneamine. *In Vitro* Cytostatic Activity, DNA Modification, and Interstrand Cross-Link Studies, *Inorg. Chem.*, 1996, **35**(18), 5181–5187, DOI: [10.1021/ic960050y](https://doi.org/10.1021/ic960050y).
  - 22 N. Cutillas, G. S. Yello, C. De Haro, C. Vicente, V. Rodríguez and J. Ruiz, Anticancer Cyclometalated Complexes of Platinum Group Metals and Gold, *Coord. Chem. Rev.*, 2013, **257**(19–20), 2784–2797, DOI: [10.1016/j.ccr.2013.03.024](https://doi.org/10.1016/j.ccr.2013.03.024).
  - 23 M. D. Aseman, S. Aryamanesh, Z. Shojaefard, B. Hemmateenejad and S. M. Nabavizadeh, Cycloplatinated (II) Derivatives of Mercaptopurine Capable of Binding Interactions with HSA/DNA, *Inorg. Chem.*, 2019, **58**(23), 16154–16170, DOI: [10.1021/acs.inorgchem.9b02696](https://doi.org/10.1021/acs.inorgchem.9b02696).
  - 24 M. Clemente, I. H. Polat, J. Albert, R. Bosque, M. Crespo, J. Granell, C. López, M. Martínez, J. Quirante, R. Messeguer, C. Calvis, J. Badía, L. Baldomà, M. Font-Bardia and M. Cascante, Platinacycles Containing a Primary Amine Platinum(II) Compounds for Treating Cisplatin-Resistant Cancers by Oxidant Therapy, *Organometallics*, 2018, **37**(20), 3502–3514, DOI: [10.1021/acs.organomet.8b00206](https://doi.org/10.1021/acs.organomet.8b00206).
  - 25 D. V. Aleksanyan, S. G. Churusova, Z. S. Klemenkova, R. R. Aysin, E. Y. Rybalkina, Y. V. Nelyubina, O. I. Artyushin, A. S. Peregudov and V. A. Kozlov, Extending the Application Scope of Organophosphorus(V) Compounds in Palladium(II) Pincer Chemistry, *Organometallics*, 2019, **38**(5), 1062–1080, DOI: [10.1021/acs.organomet.8b00867](https://doi.org/10.1021/acs.organomet.8b00867).
  - 26 F. Reigosa-Chamorro, L. R. Raposo, P. Munín-Cruz, M. T. Pereira, C. Roma-Rodrigues, P. V. Baptista,



- A. R. Fernandes and J. M. Vila, In Vitro and in Vivo Effect of Palladacycles: Targeting A2780 Ovarian Carcinoma Cells and Modulation of Angiogenesis, *Inorg. Chem.*, 2021, **60**(6), 3939–3951, DOI: [10.1021/acs.inorgchem.0c03763](https://doi.org/10.1021/acs.inorgchem.0c03763).
- 27 R. Matsa, P. Makam, M. Kaushik, S. L. Hoti and T. Kannan, Thiosemicarbazone Derivatives: Design, Synthesis and in Vitro Antimalarial Activity Studies, *Eur. J. Pharm. Sci.*, 2019, **137**, 104986, DOI: [10.1016/j.ejps.2019.104986](https://doi.org/10.1016/j.ejps.2019.104986).
- 28 G. Kalaiarasi, S. R. J. Rajkumar, S. Dharani, F. R. Fronczek, M. S. A. Muthukumar Nadar and R. Prabhakaran, Cyclometallated Ruthenium(II) Complexes with 3-Acetyl-2-[H]-Chromene-2-One Derived CNS Chelating Ligand Systems: Synthesis, X-Ray Characterization and Biological Evaluation, *New J. Chem.*, 2018, **42**(1), 336–354, DOI: [10.1039/c7nj02877f](https://doi.org/10.1039/c7nj02877f).
- 29 G. Kalaiarasi, S. R. Jeya Rajkumar, S. Dharani, F. R. Fronczek and R. Prabhakaran, Biological Evaluation of New Organoruthenium(II) Metallates Containing 3-Acetyl-8-Methoxy-2H-Chromen-2-One Appended CNS Donor Schiff Bases, *J. Organomet. Chem.*, 2018, **866**, 223–242, DOI: [10.1016/j.jorganchem.2018.04.030](https://doi.org/10.1016/j.jorganchem.2018.04.030).
- 30 J. M. Vila, M. T. Pereira, J. M. Ortigueira, M. Graña, D. Lata, A. Suárez, J. J. Fernández, A. Fernández, M. López-Torres and H. Adams, Formation, Characterization, and Structural Studies of Novel Thiosemicarbazone Palladium(II) complexes. Crystal structures of  $[\{Pd[C_6H_4C(Et)=NN=C(S)NH_2\}]_4]$ ,  $[Pd\{C_6H_4C(Et)=NN=C(S)NH_2\}(PMePh_2)]$  and  $[\{Pd[C_6H_4C(Et)=NN=C(S)NH_2\}]_2(m-Ph_2PCH_2PPh_2)]$ , *J. Chem. Soc., Dalton Trans.*, 1999, **23**, 4193–4201, DOI: [10.1039/A906276I](https://doi.org/10.1039/A906276I).
- 31 D. Sequeira, P. V. Baptista, R. Valente, M. F. M. Piedade, M. H. Garcia, T. S. Morais and A. R. Fernandes, Cu(I) complexes as new antiproliferative agents against sensitive and doxorubicin resistant colorectal cancer cells: synthesis, characterization, and mechanisms of action, *J. Chem. Soc., Dalton Trans.*, 2021, 1845–1865, DOI: [10.1039/d0dt03566a](https://doi.org/10.1039/d0dt03566a).
- 32 P. S. Pregosin and R. W. Kuntz, in *31P and 13C NMR of Transition Metal Phosphine Complexes*, ed. P. Diehl, E. Fluck and R. Kosfeld, Springer, 1979.
- 33 J. Albert, J. Granell, J. Sales, M. Font-Bardía and X. Solans, Optically Active Exocyclic Cyclopalladated Derivatives of Benzylidene-(R)-(1-phenylethyl)amines: Syntheses and X-ray Molecular Structures of  $[Pd(2-\{(E)-(R)-CHMeN=CH-2',6'-Cl_2C_6H_3\}C_6H_4)Cl(PPh_3)]$  and  $[Pd(2-\{(Z)-(R)-CHMeN=CH-2',6'-F_2C_6H_3\}C_6H_4)I(PPh_3)]$ , *Organometallics*, 1995, **14**, 1393–1404.
- 34 Promega Corporation. CellTiter 96 @ Aqueous One Solution Cell Proliferation Assay. [accessed 03-01-2023] <https://pl.promega.com/resources/protocols/technical-bulletins/0/celltiter-96-aqueous-one-solution-cell-proliferation-assay-system-protocol/2012>.
- 35 G. Indrayanto, G. S. Putra and F. Suhud, *Validation of in vitro bioassay methods: Application in herbal drug research. Profiles of Drug Substances, Excipients and Related Methodology*, Elsevier Inc., 2021, vol. 46.
- 36 C. Roma-Rodrigues, R. Mendes, P. V. Baptista and A. R. Fernandes, Targeting tumor microenvironment for cancer therapy, *Int. J. Mol. Sci.*, 2019, **20**, 840, DOI: [10.3390/ijms20040840](https://doi.org/10.3390/ijms20040840).
- 37 N. Svahn, A. J. Moro, C. Roma-Rodrigues, R. Puttreddy, K. Rissanen, P. V. Baptista, A. R. Fernandes, J. C. Lima and L. Rodríguez, The Important Role of the Nuclearity, Rigidity, and Solubility of Phosphane Ligands in the Biological Activity of Gold(I) Complexes, *Chem. – Eur. J.*, 2018, **24**(55), 14654–14667, DOI: [10.1002/chem.201802547](https://doi.org/10.1002/chem.201802547).
- 38 K. Choroba, B. Machura, A. Szlapa-Kula, J. G. Malecki, L. Raposo, C. Roma-Rodrigues, S. Cordeiro, P. V. Baptista and A. R. Fernandes, Square Planar Au(III), Pt(II) and Cu(II) Complexes with Quinoline-Substituted 2,2':6',2''-Terpyridine Ligands: From in Vitro to in Vivo Biological Properties, *Eur. J. Med. Chem.*, 2021, **218**, 113404.
- 39 P. Nicholas, Cheremisinoff. Elemental and Structural Characterization Tests, in *Polymer Characterization: Laboratory Techniques and Analysis*, 1996, pp. 43–81.
- 40 M. Van Engeland, L. J. W. Nieland, F. C. S. Ramaekers, B. Schutte and C. P. M. Reutelingsperger, Annexin V-Affinity assay: A review on an apoptosis detection system based on Phosphatidylserine Exposure, *Cytometry*, 1998, **9**, 1–9.
- 41 K. Emoto, N. Toyama-Sorimachi, H. Karasuyama, K. Inoue and M. Umeda, Exposure of phosphatidylethanolamine on the surface of apoptotic cells, *Exp. Cell Res.*, 1997, **232**, 430–434.
- 42 Z. Darzynkiewicz, G. Juan, X. Li, W. Gorczyca, T. Murakami and F. Traganos, Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis), *Cytometry*, 1997, **27**, 1–20.
- 43 Q.-P. Qin, S.-L. Wang, M.-X. Tan, Y.-C. Liu, T. Meng, B.-Q. Zou and H. Liang, Synthesis of two platinum(II) complexes with 2-methyl-8-quinolinol derivatives as ligands and study of their antitumor activities, *Eur. J. Med. Chem.*, 2019, **161**, 334–342.
- 44 F. Mihlon, C. E. Ray and W. Messersmith, Chemotherapy agents: A primer for the interventional radiologist, *Semin. Intervent. Radiol.*, 2010, **27**, 384–390.
- 45 A. M. Meredith and C. R. Dass, Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism, *J. Pharm. Pharmacol.*, 2016, **68**, 729–741.
- 46 E. Khodapasand, N. Jafarzadeh, F. Farrokhi, B. Kamalidehghan and M. Houshmand, Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer?, *Iran. Biomed. J.*, 2015, **19**, 69–75.
- 47 B. Kulsoom, T. S. Shamsi, N. A. Afsar, Z. Menom, N. Ahmed and S. N. Hasnain, Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: Are we ready for bcl-2-directed therapy?, *Cancer Manage. Res.*, 2018, **10**, 403–416.
- 48 C. M. Pfeffer and A. T. K. Singh, Apoptosis: A target for anti-cancer therapy, *Int. J. Mol. Sci.*, 2018, **19**.
- 49 J. D. Ly, D. R. Grubb and A. Lawen, The mitochondrial membrane potential ( $\Delta\psi(m)$ ) in apoptosis; an update, *Apoptosis*, 2003, **8**, 115–128.



- 50 A. Perelman, C. Wachtel, M. Cohen, S. Haupt, H. Shapiro and A. Tzur, JC-1: Alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry, *Cell Death Dis.*, 2012, **3**, 1–7.
- 51 K. F. Cooper, Till death do us part: The marriage of autophagy and apoptosis, *Oxid. Med. Cell. Longevity*, 2018, **2018**, 4701275, DOI: [10.1155/2018/4701275](https://doi.org/10.1155/2018/4701275).
- 52 M. S. D'Arcy, Cell death: a review of the major forms of apoptosis, necrosis and autophagy, *Cell Biol. Int.*, 2019, **43**, 582–592.
- 53 S. Zaman, R. Wang and V. Gandhi, Targeting the apoptosis pathway in hematologic malignancies, *Leuk. Lymphoma*, 2014, **55**, 1980–1992.
- 54 K. Suntharalingam, J. J. Wilson, W. Lin and S. J. Lippard, A dual-targeting, p53-independent, apoptosis-inducing platinum(II) anticancer complex, [Pt(BDIQQ)]Cl, *Metallomics*, 2014, **6**(3), 437–443.
- 55 C. Roma-Rodrigues, G. Malta, D. Peixoto, L. M. Ferreira, P. V. Baptista, A. R. Fernandes and P. S. Branco, Synthesis of new hetero-arylidene-9(10H)-anthrone derivatives and their biological evaluation, *Bioorg. Chem.*, 2020, **99**, 103849.
- 56 T. Ichimiya, T. Yamakawa, T. Hirano, Y. Yokoyama, Y. Hayashi, D. Hirayama, K. Wagatsuma, T. Itoi and H. Nakase, Autophagy and autophagy-related diseases: A review, *Int. J. Mol. Sci.*, 2020, **21**, 1–21.
- 57 F. Yang, K. Xu, Y.-G. Zhou and T. Ren, Insight into autophagy in platinum resistance of cancer, *Int. J. Clin. Oncol.*, 2023, **28**, 354–362.
- 58 I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F. Cacciatore, D. Bonaduce and P. Abete, Oxidative stress, aging, and diseases, *Clin. Interventions Aging*, 2018, **13**, 757–772.
- 59 Abcam. DCFDA/H2DCFDA - Cellular ROS Assay Kit (ab113851). Oxidative Stress [accessed 04-01-2023] <https://www.abcam.com/dcfda-h2dcfda-cellular-ros-assay-kit-ab113851.html>.
- 60 D. Kashyap, A. Sharma, V. Garg, H. S. Tuli, G. Kumar, M. Kumar and T. Mukherjee, Reactive Oxygen Species (ROS): an Activator of Apoptosis and Autophagy in Cancer, *J. Biol. Chem. Sci.*, 2016, **3**, 256–264.
- 61 Q. Xie, G. Lan, Y. Zhou, J. Huang, Y. Liang, W. Zheng, X. Fu, C. Fan and T. Chen, Strategy to enhance the anti-cancer efficacy of X-ray radiotherapy in melanoma cells by platinum complexes, the role of ROS-mediated signaling pathways, *Cancer Lett.*, 2014, **354**, 58–67.
- 62 F. Finetti and L. Trabalzini, Bidimensional In Vitro Angiogenic Assays to Study CCM Pathogenesis: Endothelial Cell Proliferation and Migration, in *Methods in Molecular Biology*, 2020, vol. 2152, pp. 377–385.
- 63 A. K. M. N. Hossian and G. Mattheolabakis, Cellular Migration Assay: An In Vitro Technique to Simulate the Wound Repair Mechanism, in *Methods in Molecular Biology*, 2021, vol. 2193, pp. 77–83.
- 64 D. Kobelt, W. Walther and U. S. Stein, Real-Time Cell Migration Monitoring to Analyze Drug Synergism in the Scratch Assay Using the IncuCyte System, in *Methods in Molecular Biology*, 2021, vol. 2294, pp. 133–142.

